Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation
ConclusionsWe explored use of GBM to identify potential subgroups with different treatment effect. Dabigatran's superiority to warfarin at prevention of thromboembolism may be greater in secondary than primary prevention. In practice, secondary prevention patients are more often treated with warfarin.
Source: Pharmacoepidemiology and Drug Safety - Category: Drugs & Pharmacology Authors: Shirley V. Wang, Krista F. Huybrechts, Michael A. Fischer, Jessica M. Franklin, Robert J. Glynn, Sebastian Schneeweiss, Joshua J. Gagne Tags: ORIGINAL REPORT Source Type: research
More News: Atrial Fibrillation | Bleeding | Coumadin | Databases & Libraries | Drugs & Pharmacology | Pradaxa | Study | Thrombosis | Warfarin